A/Prof Mustafa Khasraw is a medical oncologist at The Royal North Shore Hospital and the Northern Cancer Institute, St Leonards, Sydney. Mustafa has trained and worked in oncology at several countries, he earned his MD from the University of Groningen in the Netherlands and has worked as an oncology fellow at Addenbrookes hospital in Cambridge UK (2005 -2007).

A/Prof Khasraw trained as a medical oncologist at The Royal North Shore Hospital in Sydney (2007 – 2010) and went on to complete a fellowship at Memorial Sloan-Kettering Cancer Centre in New York (2010 – 2011). In 2011 he returned to Australia and took on a position as a consultant medical oncologist at Geelong and Royal Melbourne Hospitals until 2015 when he returned to RNSH.

Currently, he is a senior research fellow and clinical lead at the National Health Medical Research Council Clinical Trial Centre at The University of Sydney. He also holds a leading role in several clinical and translational programs including being a TCE leader for Sydney Vital.


Research Interests

  • Clinical Trials
  • Neuro-oncology
  • Breast Cancer
  • Neuroendocrine Tumours

A/Prof Khasraw is principal investigator on phase I,II and III clinical trials in solid tumours. He’s also the chief investigator on NHMRC funded research into the treatment and biomarker discovery for glioblastoma (GBM), neuroendocrine (NET) and a number of other cancer types.

Additional analyses of the NEONAB trial – Sydney Catalyst Translational Cancer Research/CRE transBCR Grant

University of Sydney 2017

A 2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG)

National Health and Medical Research Council 2017

A Randomised Phase II Study of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC

National Health and Medical Research Council (NHMRC)/Project Grants 2016

NABNEC: A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Specialised Therapeutics Australia Pty Ltd/Research Contract 2016

VERTU – VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma

Cancer Council New South Wales/Priority-driven Collaborative Cancer Research Scheme 2016

VERTU – VEliparib, Radiotherapy and Temozolimde trial in newly diagnosed Unmethylated MGMT Glioblastoma

Cure Brain Cancer Foundation/Research Grant 2015

Year Award/ Honour Institution
2018 Elected to the Fellowship of the College of Physicians (UK) The Royal College of Physicians UK- London
2016 MOGA ASM best oral presentation award The Medical Oncology Group of Australia
2013 AGITG best clinical trial concept award for proposing the NABNEC study Australasian Gastro-Intestinal Trials Group
2012 Clinical Investigatorship Award The Viertel Foundation
2011 The inaugural UNICORN foundation award in neuroendocrine tumours The Unicorn Foundation
2009 R Vanderfield Scholarship Royal North Shore Hospital
2008 Best Registrar Teacher Award Faculty of Medicine, University of Sydney
2008 Australia and Asia Pacific Clinical Oncology Research Development Fellowship Award Australia and Asia Pacific Clinical Oncology Research Development

Efficacy and Safety of Sunitinib in Patients With Well-Differentiated Pancreatic Neuroendocrine Tumours. Raymond E, Kulke M, Qin SK, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru A, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein P, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan G, Morizane C, Galdy S, Khosravan R, Fernandez K, Rosbrook B, Fazio N. Neuroendocrinology. 2018 Jul 10. doi: 10.1159/000491999.

Correction to: Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.Brennan-Olsen S, Vogrin S, Holloway KL, Page RS, Sajjad MA, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Pedler D, Sutherland A, Venkatesh S, Williams LJ, Duque G, Graves S, Lorimer M, Pasco JA. Arch Osteoporos. 2018 Jul 9;13(1):75. doi: 10.1007/s11657-018-0484-y.

Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. Back M, Rodriguez M, Jayamanne D, Khasraw M, Lee A, Wheeler H.Clin Oncol (R Coll Radiol). 2018 Jul 3. pii: S0936-6555(18)30288-7. doi: 10.1016/j.clon.2018.06.005. [Epub ahead of print]

Profiles of Brain Metastases: Prioritization of Therapeutic Targets.Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O’Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31624. [Epub ahead of print]

Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M.Pract Radiat Oncol. 2018 Jul – Aug;8(4):230-238. doi: 10.1016/j.prro.2018.01.006. Epub 2018 Jan 31.

The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.Muscat AM, Wong NC, Drummond KJ, Algar EM, Khasraw M, Verhaak R, Field K, Rosenthal MA, Ashley DM.Oncotarget. 2017 Dec 15;9(8):7844-7858. doi: 10.18632/oncotarget.23541. eCollection 2018 Jan 30.

Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.GLASS Consortium .Neuro Oncol. 2018 Jun 18;20(7):873-884. doi: 10.1093/neuonc/noy020.

Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.Wann A, Tully PA, Barnes EH, Lwin Z, Jeffree R, Drummond KJ, Gan H, Khasraw M.J Neurooncol. 2018 Apr;137(2):409-415. doi: 10.1007/s11060-017-2731-2. Epub 2018 Jan 2.

The epidemiology of hip fractures across western Victoria, Australia.Holloway KL, Sajjad MA, Mohebbi M, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.Bone. 2018 Mar;108:1-9. doi: 10.1016/j.bone.2017.12.007. Epub 2017 Dec 8.

Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.Brennan-Olsen S, Vogrin S, Holloway KL, Page RS, Sajjad MA, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Pedler D, Sutherland A, Venkatesh S, Williams LJ, Duque G, Pasco JA.Arch Osteoporos. 2017 Nov 6;12(1):97. doi: 10.1007/s11657-017-0396-2. Erratum in: Arch Osteoporos. 2018 Jul 9;13(1):75.

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T.Asia Pac J Clin Oncol. 2018 Jun;14(3):256-263. doi: 10.1111/ajco.12785. Epub 2017 Nov 6.

Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L, Giuffre B, Baron-Hay S, Khasraw M.Intern Med J. 2018 Jun;48(6):699-705. doi: 10.1111/imj.13617.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

Combination of palbociclib and radiotherapy for glioblastoma.Whittaker S, Madani D, Joshi S, Chung SA, Johns T, Day B, Khasraw M, McDonald KL.Cell Death Discov. 2017 Jul 3;3:17033. doi: 10.1038/cddiscovery.2017.33. eCollection 2017.

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810. doi: 10.1016/j.ijrobp.2017.02.028. Epub 2017 Feb 21.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702.

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL.Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017.

Immune Checkpoint Inhibitors for Brain Metastases.Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.Jue TR, Nozue K, Lester AJ, Joshi S, Schroder LB, Whittaker SP, Nixdorf S, Rapkins RW, Khasraw M, McDonald KL.J Transl Med. 2017 Mar 17;15(1):61. doi: 10.1186/s12967-017-1164-1.

Immune Checkpoint Inhibitors in Gliomas.Tan AC, Heimberger AB, Khasraw M.Curr Oncol Rep. 2017 Apr;19(4):23. doi: 10.1007/s11912-017-0586-5. Review.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

Reply to Dr Altundag from the authors of ‘Management of breast cancer brain metastases; a practical review’.Phillips C, Jeffree R, Khasraw M.Breast. 2017 Aug;34:133. doi: 10.1016/j.breast.2016.11.026. Epub 2016 Dec 9.

Management of breast cancer brain metastases: A practical review.Phillips C, Jeffree R, Khasraw M.Breast. 2017 Feb;31:90-98. doi: 10.1016/j.breast.2016.10.006. Epub 2016 Nov 6. Review.

Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia).Sajjad MA, Holloway KL, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.J Public Health Res. 2016 Aug 19;5(2):678. eCollection 2016 Aug 19.

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K.Clin Transl Oncol. 2017 Mar;19(3):273-278. doi: 10.1007/s12094-016-1547-4. Epub 2016 Sep 21. Review.

Prioritization schema for immunotherapy clinical trials in glioblastoma.Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments.Wong SF, Norman R, Dunning TL, Ashley DM, Khasraw M, Hayes TM, Collins I, Lorgelly PK.J Natl Compr Canc Netw. 2016 Mar;14(3):311-9. Epub 2016 Mar 8.

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H.J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2.


Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.Wann A, Ashley D, Khasraw M.Support Care Cancer. 2016 Jul;24(7):3023-8. doi: 10.1007/s00520-016-3124-3. Epub 2016 Feb 18.

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Khasraw M, Ananda S, Michael M.Expert Rev Anticancer Ther. 2016;16(4):391-401. doi: 10.1586/14737140.2016.1146135. Epub 2016 Feb 17. Review.

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, Ward A, Wang L, Wei MQ, AlShamaileh H, Chen L, She X, Lin J, Kong L, Shigdar S, Duan W.Theranostics. 2015 Oct 20;5(12):1456-72. doi: 10.7150/thno.11692. eCollection 2015.

Evolving management of low grade glioma: No consensus amongst treating clinicians.Field KM, Rosenthal MA, Khasraw M, Sawkins K, Nowak AK.J Clin Neurosci. 2016 Jan;23:81-87. doi: 10.1016/j.jocn.2015.05.038. Epub 2015 Oct 23.

Retrospective analysis of cancer survival across South-Western Victoria in Australia.Wong SF, Matheson L, Morrissy K, Pitson G, Ashley DM, Khasraw M, Lorgelly PK, Henry MJ.Aust J Rural Health. 2016 Apr;24(2):79-84. doi: 10.1111/ajr.12203. Epub 2015 Jun 29.

CDK4/6 inhibitors in breast cancer.Dukelow T, Kishan D, Khasraw M, Murphy CG.Anticancer Drugs. 2015 Sep;26(8):797-806. doi: 10.1097/CAD.0000000000000249. Review.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group.N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.

Antiangiogenic therapy for high-grade glioma.Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review.

Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M.Asia Pac J Clin Oncol. 2014 Sep;10(3):273-8. doi: 10.1111/ajco.12231.

Patterns of care in adult medulloblastoma: results of an international online survey.Cosman R, Brown CS, DeBraganca KC, Khasraw M.J Neurooncol. 2014 Oct;120(1):125-9. doi: 10.1007/s11060-014-1525-z. Epub 2014 Jul 16.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.Khasraw M, Ameratunga M, Grommes C.Expert Opin Biol Ther. 2014 May;14(5):729-40. doi: 10.1517/14712598.2014.898060. Epub 2014 Mar 22. Review.

Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry.Gupta S, Tran T, Luo W, Phung D, Kennedy RL, Broad A, Campbell D, Kipp D, Singh M, Khasraw M, Matheson L, Ashley DM, Venkatesh S.BMJ Open. 2014 Mar 17;4(3):e004007. doi: 10.1136/bmjopen-2013-004007.

Brain metastases in breast cancer.Sim HW, Morris PG, Patil S, Khasraw M.Expert Rev Anticancer Ther. 2014 Feb;14(2):173-83. doi: 10.1586/14737140.2014.863468. Epub 2013 Dec 2. Review.

Emerging pharmacotherapy for cancer patients with cognitive dysfunction.Davis J, Ahlberg FM, Berk M, Ashley DM, Khasraw M.BMC Neurol. 2013 Oct 24;13:153. doi: 10.1186/1471-2377-13-153. Review.

Small bowel video capsule endoscopy: an overview.Mustafa BF, Samaan M, Langmead L, Khasraw M.Expert Rev Gastroenterol Hepatol. 2013 May;7(4):323-9. doi: 10.1586/egh.13.20. Review.

Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Khasraw M, Yap SY, Ananda S.Expert Rev Anticancer Ther. 2013 Apr;13(4):451-9. doi: 10.1586/era.13.22. Review.

Alternative targeted therapy for early Her2 positive breast cancer.Harvey SL, Khasraw M.Gland Surg. 2013 Feb;2(1):42-5. doi: 10.3978/j.issn.2227-684X.2013.02.06. No abstract available.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M.Cancer. 2013 Apr 1;119(7):1344-8. doi: 10.1002/cncr.27842. Epub 2012 Nov 16.

Using lithium as a neuroprotective agent in patients with cancer.Khasraw M, Ashley D, Wheeler G, Berk M.BMC Med. 2012 Nov 2;10:131. doi: 10.1186/1741-7015-10-131. Review.

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.Khasraw M, Bell R.Expert Rev Anticancer Ther. 2012 Aug;12(8):1005-13. doi: 10.1586/era.12.62. Review.

Colorectal cancer: is the incidence rising in young Iraqi patients?Sheet SY, Sheikha AK, Saeed AM, Ameen HA, Mohammed SS, Khasraw M.Asia Pac J Clin Oncol. 2012 Dec;8(4):380-1. doi: 10.1111/j.1743-7563.2012.01524.x. Epub 2012 May 2. Review. No abstract available.

Bevacizumab for the treatment of high-grade glioma.Khasraw M, Simeonovic M, Grommes C.Expert Opin Biol Ther. 2012 Aug;12(8):1101-11. doi: 10.1517/14712598.2012.694422. Epub 2012 Jun 5. Review.

Epirubicin: is it like doxorubicin in breast cancer? A clinical review.Khasraw M, Bell R, Dang C.Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Review.

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.Khasraw M, Holodny A, Goldlust SA, DeAngelis LM.Ann Oncol. 2012 Feb;23(2):458-63. doi: 10.1093/annonc/mdr148. Epub 2011 May 4.

Neurological complications of systemic cancer.Khasraw M, Posner JB.Lancet Neurol. 2010 Dec;9(12):1214-1227. doi: 10.1016/S1474-4422(10)70220-9. Review.

The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?Khasraw M, Brogi E, Seidman AD.Curr Oncol Rep. 2011 Feb;13(1):17-25. doi: 10.1007/s11912-010-0137-9. Review.

Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.Khasraw M, Townsend A, Price T, Hart J, Bell D, Pavlakis N.Intern Med J. 2010 Jun;40(6):453-8. doi: 10.1111/j.1445-5994.2010.02245.x.

Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.Murphy CG, Khasraw M, Seidman AD.Breast Cancer Res Treat. 2010 Jul;122(1):177-9. doi: 10.1007/s10549-010-0925-9. Epub 2010 May 11. No abstract available.

Advances in the treatment of malignant gliomas.Khasraw M, Lassman AB.Curr Oncol Rep. 2010 Jan;12(1):26-33. doi: 10.1007/s11912-009-0077-4. Review.

Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma.Khasraw M, Lassman AB.Nat Rev Neurol. 2009 Dec;5(12):646-7. doi: 10.1038/nrneurol.2009.194. No abstract available.

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G.Ann Oncol. 2010 Jun;21(6):1302-7. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.

Management of advanced neuroendocrine tumors with hepatic metastasis.Khasraw M, Gill A, Harrington T, Pavlakis N, Modlin I.J Clin Gastroenterol. 2009 Oct;43(9):838-47. doi: 10.1097/MCG.0b013e3181b152a1. Review.

Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?Khasraw M, Baron-Hay S.Ann Oncol. 2009 Jul;20(7):1282-3. doi: 10.1093/annonc/mdp305. No abstract available.

Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?Khasraw M, Bell D, Wheeler H.J Clin Neurosci. 2009 Jun;16(6):854-5. doi: 10.1016/j.jocn.2008.09.005. Epub 2009 Mar 20.

For more information please contact

Email: [email protected]

Find out more ..